Characteristics of Real-world Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Initiating Subcutaneous Efgartigimod in United States

Real-world Healthcare Resource Utilization Following Initiation of Subcutaneous IgPro20 Among U.S. Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Clinical Experience With Subcutaneous Efgartigimod PH20 in Patients With Newly Diagnosed Chronic Inflammatory Demyelinating Polyradiculoneuropathy